Cargando…
Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey
BACKGROUND/AIM: The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. MATERIALS AND METHODS: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated. RESULTS: The median age at ruxolitinib initiation was 62 (28–87) a...
Autores principales: | SOYER, Nur, ALİ, Rıdvan, TURGUT, Mehmet, C. HAZNEDAROĞLU, İbrahim, YILMAZ, Fergün, AYDOĞDU, İsmet, PİR, Ali, KARAKUŞ, Volkan, ÖZGÜR, Gökhan, KİS, Cem, CERAN, Funda, İLHAN, Gül, ÖZKAN, Melda, ASLANER, Müzeyyen, İNCE, İdris, YAVAŞOĞLU, İrfan, GEDİZ, Füsun, SÖNMEZ, Mehmet, GÜVENÇ, Birol, ÖZET, Gülsüm, KAYA, Emin, VURAL, Filiz, ŞAHİN, Fahri, TÖBÜ, Mahmut, DURUSOY, Raika, SAYDAM, Güray |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Scientific and Technological Research Council of Turkey
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283435/ https://www.ncbi.nlm.nih.gov/pubmed/33315343 http://dx.doi.org/10.3906/sag-1812-70 |
Ejemplares similares
-
Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms
por: Soyer, Nur, et al.
Publicado: (2017) -
Extramedullary Relapse in a CML Patient after Allogeneic Stem Cell Transplantation
por: Yilmaz, Asu Fergun, et al.
Publicado: (2017) -
The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia
por: Saydam, Guray, et al.
Publicado: (2022) -
Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia
por: Saydam, Guray, et al.
Publicado: (2022) -
PB1937: A RARE, DIFFICULT- TO- DIAGNOSE DISEASE; LANGERHANS CELL HISTIOCYTOSIS – A SINGLE CENTRE EXPERIENCE
por: Tüzün, Betül Kübra, et al.
Publicado: (2023)